Key result
Prolonged daily oral treatment with spirapril prevented the development of hypertension in spontaneously hypertensive rats, with a concomitant decrease in aortic ACE activity.
Why the study?
Does spirapril prevent the development of hypertension and reduce vascular ACE activity in spontaneously hypertensive rats?
Population
Spontaneously hypertensive rats (SHR) and Wistar-Kyoto (WKY) normotensive control rats (ages 4 to 20 weeks)
Comparison
Spirapril vs Untreated SHR and WKY normotensive control rats
Design
Preclinical
Follow-up
8 weeks
Authors
Loading...
Spirapril's effect in rat models leaves open preventive use in humans; supports further mechanistic study of vascular ACE in hypertension.
Does spirapril prevent the development of hypertension and reduce vascular ACE activity in spontaneously hypertensive rats?
Increased vascular ACE activity may play an essential role in the development and maintenance of hypertension in spontaneously hypertensive rats, which can be prevented by the ACE inhibitor spirapril.
Okunishi et al. (1991) studied Hypertension. Spirapril vs. Wistar-Kyoto (WKY) normotensive control rats / untreated SHR was evaluated on Blood pressure and ACE activity in vascular tissue. Prolonged daily oral treatment with spirapril prevented the development of hypertension in spontaneously hypertensive rats, with a concomitant decrease in aortic ACE activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: